Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novo Nordisk’s Wegovy In Medicare Part D: Coverage May Not Be The Only Problem

Executive Summary

Prospect of facing price negotiation in Part D may lead Novo Nordisk to consider earlier-than-currently-planned generic competition for its older semaglutide drug for diabetes, Ozempic.

You may also be interested in...



Obesity Drug Costs: Limited-Time Use, Then Shift To Cheaper Maintenance Floated By Sen. Cassidy

Sen. Bill Cassidy and an obesity advocacy group suggest studies test whether obesity patients could be switched to a cheaper maintenance medicine or diet after their initial weight loss on GLP-1s. Approval of Lilly’s Zepbound is a reminder of the expected surge in utilization for the class.

Obesity Drugs: Jury's Still Out On Potential US Health Care Savings, CBO Says

The Congressional Budget Office’s perception of the limits of current data on the broader health benefits of anti-obesity medications highlights the challenges facing legislation enabling Medicare coverage for the drugs.

Wegovy’s Cardiovascular Benefits May Improve, But Not Transform, Insurance Coverage In Obesity

Novo Nordisk’s obesity drug lowered adverse cardiovascular events by an impressive 20% in a pivotal study. However, payers may still want data on how paying for obesity drugs could lower their overall medical expenses.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS147984

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel